Searchable abstracts of presentations at key conferences in endocrinology

ea0035p905 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Effect of pasireotide on GH, IGF1, IGFBP2, IGFBP3, HbA1C and glucose in patients with inadequately controlled acromegaly: exploratory results from a multicentre, randomized, 24-week study (PAOLA)

Schmid Herbert , Brue Thierry , Colao Annamaria , Gadelha Monica , Shimon Ilan , Kapur Karen , D'Amato Lisa , Pedroncelli Alberto , Fleseriu Maria

Background: The PAOLA study assessed the efficacy/safety of pasireotide LAR vs continued treatment with octreotide LAR/lanreotide Autogel in patients with inadequately controlled acromegaly. An exploratory objective was to measure changes in various associated biomarkers, including IGF1 and IGFBP2 (released from white fat cells and known to prevent insulin resistance), glucose and HbA1c.Methods: Adult patients (GH >2.5 μg/l and IGF1 >1.3&#21...

ea0070aep718 | Pituitary and Neuroendocrinology | ECE2020

Evaluation of early predictors of metabolic syndrome in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET)

Bottiglieri Filomena , Modica Roberta , Barrea Luigi , de Cicco Federica , Minotta Roberto , Muscogiuri Giovanna , Savastano Silvia , Faggiano Antongiulio , Colao Annamaria

Metabolic syndrome and obesity (MetS) are supposed to have a role in cancer but data analysing their association with GEP-NET are lacking. Aim of this study was to explore the association of early predictors of MetS with GEP-NET, usingas tools Fatty Liver Index (FLI), a predictor of non-alcoholic fatty liver disease (NAFLD)and Visceral Adiposity Index (VAI), a gender-specific indicator of adipose dysfunction. A cross-sectional case-control observational study was conducted. VA...

ea0022p49 | Adrenal | ECE2010

In vitro effect of dopastatins on hormone secretion in adrenal tumors

Pivonello Claudia , Napolitano Tiziana , De Leo Monica , Cozzolino Alessia , Vitale Pasquale , Lombardi Gaetano , Colao Annamaria , Pivonello Rosario

Somatostatin (SSTRs) and dopamine (DRs) receptors are expressed in adrenal tumors. It has been demonstrated in pituitary and neuroendocrine tumors that somatostatin-dopamine chimeric molecules, namely dopastatins, which bind both somatostatin (SST2 and/or SST5) and dopamine (D2) receptors, exert a more potent action compared with the single receptor agonists in experimental settings. The aims of this study were to evaluate the expression of DRs and SSTRs, and the effects of do...

ea0022p405 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Cinacalcet hydrochloride effectively controlled primary hyperparathyroidism in patients unresponsive to bisphosphonates

Faggiano Antongiulio , Somma Carolina Di , Milone Francesco , Ramundo Valeria , Rota Francesca , Vuolo Laura , Guerra Ermelinda , Colao Annamaria

Context: Until now the role of medical therapy in patients with primary hyperparathyroidism (PHP) was mainly based on the use of bisphosphonates. Recently, cinacalcet hydrochloride was reported to be effective in control hypercalcemia in PHP. The aim of this study was to evaluate the efficacy of cinacalcet in PHP patients who were not effectively controlled with alendronate.Patients and methods: Fourteen PHP patients (mean age 64.1±2.6) were include...

ea0022p511 | Growth factors | ECE2010

IGF1 and IGFBP3 levels in relapsing-remitting and secondary progressive multiple sclerosis (MP)

Di Somma Carolina , Lanzillo Roberta , Savanelli Maria Cristina , Scarano Elisabetta , Contaldi Paola , Lombardi Gaetano , Morra Vincenzo Brescia , Colao Annamaria

Background: There is a growing body of evidence of an alteration in GH/IGF1 axis in neurological diseases. IGF1 and IGFBP3 serum levels are reported to be similar in controls, relapsing remitting (RR) MS and primary progressive (PP) MS patients, but in RR patients on IFN therapy they were found to be higher then in controls. IGFBP3 was found to correlate to progression index in PPMS.Objective: To compare IGF1 and IGFBP3 serum levels in RR MS and secondar...

ea0022p657 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Cabergoline treatment in Cushing's disease: effect of cabergoline withdrawal in patients with normalized cortisol secretion after long-term treatment

Pivonello Rosario , De Leo Monica , Cozzolino Alessia , Vitale Pasquale , De Martino Maria Cristina , Simeoli Chiara , Lombardi Gaetano , Colao Annamaria

The dopamine agonist cabergoline has been found to be effective in inducing normalization of cortisol secretion in 25–50% of patients with Cushing’s disease after long-term treatment. Moreover, tumor shrinkage have been documented in selected patients with pituitary corticotroph tumors. The aim of the present study was to evaluate the effect of cabergoline withdrawal in patients with a stable normalization of cortisol secretion and stable or absent visualization of p...

ea0022p661 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

SSTR5 ligand binding domain immunohistological detection in pituitary adenomas using Y-SSTR5 a new mouse monoclonal antibody

Rossi Valentina , Staibano Stefania , Del Basso De Caro Laura , Bellastella Giuseppe , Ilardi Gennaro , Cavallo Luigi , Colao Annamaria , Agostino Sinisi Antonio

Polyclonal antibodies against somatostatin receptors (SSTRs) available up to now recognizing intracellular sites of receptors and their recycling products do not detect bioactive ligand binding domains (LBDs) and are of limited performance in paraffin-embedded tissues. Aim of this study was to evaluate by immunohistochemistry the expression of SSTR5 on an archival series of pituitary tumors using a new MoAbs against the SST-binding domain (Y-SSTR5).Metho...

ea0020p26 | Adrenal | ECE2009

Cardiac structure and function in patients with adrenal incidentaloma: an echocardiographic study

De Leo Monica , Galderisi Maurizio , De Martino Maria Cristina , Cozzolino Alessia , Colao Annamaria , Pivonello Rosario , Lombardi Gaetano

Subclinical Cushing’s syndrome (SCS) is a mild autonomous cortisol hypersecretion without specific clinical syndrome of glucocorticoid excess. The aim of this study was to compare cardiac structure and function in patients with adrenal incidentaloma. Twenty patients and 20 sex- and age-matched healthy controls entered the study: among patients, 11 had SCS and the remaining nine had normal cortisol secretion All patients and controls were submitted to Doppler echocardiogra...

ea0020p193 | Endocrine tumours and neoplasia | ECE2009

Effectiveness and safety of combined therapy with low dose ketoconazole and cabergoline in patients with Cushing’s disease partially responsive to monotherapy with cabergoline

Pivonello Rosario , De Leo Monica , De Martino MariaCristina , Cozzolino Alessia , Auriemma Renata S , Galdiero Mariano , Lombardi Gaetano , Colao Annamaria

The first-line treatment of Cushing’s disease is surgery, although it is effective in inducing a long-term remission in around 50% of patients with Cushing’s disease (CD). Nowadays, no pituitary tumor-directed medical treatment is available with the exception of cabergoline, which has been recently demonstrated to control cortisol secretion without major side effects in around 40% of patients with Cushing’s disease. Cabergoline has been recently demonstrated to ...

ea0016p394 | Neuroendocrinology | ECE2008

Growth hormone (GH) treatment on atherosclerosis: results of a 5 years open, prospective, controlled study in male patients with severe GH deficiency

Colao Annamaria , Di Somma Carolina , Spiezia Stefano , Savastano Silvia , Rota Francesca , Savanelli Maria Cristina , D'Andrea Marianna , Lombardi Gaetano

Background: Severe GH deficiency (GHD) is associated with, increased cardiovascular (CV) risk and intima-media thickness (IMT) at major arteries.Objective: To investigate the long-term (5-years) effects of GH replacement on insulin resistance (IR) syndrome (IRS) (at least two of: triglycerides levels ≥1.7 mmol/l, HDL-cholesterol levels ≤1.0 mmol/l, blood pressure above 130/85 mmHg, fasting glucose 6.1–7 or 2 h after glucose 7.7–11.1...